Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML.
Arvidsson Kvissberg M, Nilsson C, Landberg N, Österroos A, Papageorgiou A, Uggla B, Lazarevic V, Deneberg S, Jädersten M
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.